Skip To Main Content
Gregory L. Verdine on Muck Rack

Gregory L. Verdine

Boston
As seen in: Nature, The Journal of Biological Chemistry
Professor, Harvard University; Founder, President, CEO FogPharma & LifeMine Tx; Founder & BOD Member WAVE Life Sciences, Venture Partner, WuXi Ventures
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gregory L.

Contact Gregory L., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mirror-image ligand discovery enabled by single-shot fast-flow synthesis of D-proteins - Nature Communications

|
By Tara Travaline, Jean-Marie Swiecicki, Gregory L. Verdine, John McGee
| Nature Verified
Abstract Widespread adoption of mirror-image biological systems presents difficulties in accessing the requisite D-protein substrates. In particular, mirror-image phage display has the potential for high-throughput generation of biologically stable macrocyclic D-peptide binders with potentially unique recognition modes but is hindered by the individualized optimization required for D-protein chemical synthesis.
Open in Who Shared Issue with article?

Recognition and reprogramming of E3 ubiquitin ligase surfaces by α-helical peptides - Nature Communications

|
By Kunhua Li, Tara Travaline, Jean-Marie Swiecicki, Jessica Ramirez, Gregory L. Verdine, Ty M. Thomson, Sean Litchman
| Nature Verified
Abstract Molecules that induce novel interactions between proteins hold great promise for the study of biological systems and the development of therapeutics, but their discovery has been limited by the complexities of rationally designing interactions between three components, and because known binders to each protein are typically required to inform initial designs.
Open in Who Shared Issue with article?

The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members

|
By Gregory L. Verdine, Loren D. Walensky, Verdine GL, Walensky LD
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (430) Issue with article?
See all 7 articles